At Trade Talks, Generic-Drug Issue Key

By Itano, Nicole | The Christian Science Monitor, November 9, 2001 | Go to article overview
Save to active project

At Trade Talks, Generic-Drug Issue Key

Itano, Nicole, The Christian Science Monitor

One unexpected beneficiary of the US-led war on terrorism may be the millions of Africans, Indians, and others from impoverished countries besieged by the AIDS epidemic. For years, developing nations have fought with little success for the right to produce generic versions of costly, patented medications developed in the US and Europe.

But a group of more than 60 developing nations may have new leverage, heading into negotiations this weekend with the 142- member World Trade Organization, which requires consensus among members. The five-day meeting, which opens tonight in Doha, Qatar, aims to finalize an agenda for a formal round of negotiations to lower global trade barriers.

Developing nations want a guarantee that an agreement known as Trade Related Aspects of Intellectual Property Rights (TRIPS) will allow them to import generic medicines for AIDS and other epidemics.

"The issue of TRIPS and public health - this could well be the deal breaker at this conference," said Mike Moore, director general of the Geneva-based WTO. "It is an important issue, and it is, I think, turning into one of the most difficult subjects we have in front of us."

Pharmaceutical giants, which spend billions of dollars developing medications, say loosening patents threatens their ability to cover their expenses.

The staunchest hold-out against easing patents has been the US. But AIDS groups here in South Africa note the paradox of US actions. As soon as it had an anthrax scare on its own soil, the US threatened to violate the patent of Cipro, an antibiotic used to treat the disease, to make it more widely available.

"It's a very timely example of the double standard that exists," says Seco Gerard, the EU liaison on medical-access issues for the agency Medicines Sans Frontiers, which is on the front line of this battle.

Accused of hypocrisy by AIDS groups and developing nations, the US is now backing off on its hard-line stance on drug patents, offering new hope for AIDS-ravaged countries such as South Africa.

Developing nations won a major victory earlier this year when a coalition of global pharmaceutical companies dropped their lawsuit challenging a South African law that allowed the production and importation of generic versions of patented AIDS drugs, and the parallel importation of drugs sold more cheaply in other countries. Now they want that principle enshrined in law.

The TRIPS agreement currently protects the patents of drug companies. Developing nations want a loophole allowing them to import generic drugs in the case of major health epidemics such as AIDS, tuberculosis, and malaria.

"We want to tighten the interpretation so that it's clear that issues of national interest come first," says Edwin Smith, a spokesman for the South African Minister of Trade and Industry and a member of that country's delegation this weekend.

"The general concern of developing governments is that the TRIPS agreement was imbalanced, and that it favored multinational interests - that it was structured in favor of the protection of patents against the need for cheaper and more affordable medicines for the poor," says Faizel Ismail, a member of South African delegation to the meeting.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Cite this article

Cited article

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

At Trade Talks, Generic-Drug Issue Key


Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?